IRAK-4 and MyD88 deficiencies impair IgD⁺IgM⁺CD27⁺ B-cell proliferation. (A) TLR agonists enrich IgM⁺IgD⁺CD27⁺ B cells in culture of control PBMCs, but not IRAK-4– or MyD88-deficient PBMCs. Gated on CD19⁺, CD27⁺. Representative of 4 experiments. (B) Quantification of total lymphocytes, IgM⁺IgD⁺ and IgM⁻IgD⁻ CD27⁺ B cells with and without TLR stimulation. Data from 4 individuals per group. Box represents mean; whiskers represent standard error of mean. (C) Dilution of CFSE after TLR stimulation. Representative of 3 experiments. *P < .05.